Deep vein thrombosis resolution is not accelerated with increased neovascularization
| Autor: | K. Barry Deatrick, Daria M. Moaveni, Manu R. Varma, Andrea Varga, Nicholas A. Dewyer, Steven L. Kunkel, Thomas W. Wakefield, Gilbert R. Upchurch, Peter K. Henke |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Pathology medicine.medical_specialty Chemokine CXCL5 medicine.medical_treatment Basic fibroblast growth factor Neovascularization Physiologic Vena Cava Inferior Inferior vena cava Neovascularization Rats Sprague-Dawley chemistry.chemical_compound Fibrinolysis Medicine Animals cardiovascular diseases Thrombus Ultrasonography Venous Thrombosis business.industry Monocyte Interleukin-8 medicine.disease Thrombosis Rats Chemokine CXCL10 Venous thrombosis Disease Models Animal medicine.anatomical_structure medicine.vein chemistry cardiovascular system Fibroblast Growth Factor 2 Surgery medicine.symptom business Cardiology and Cardiovascular Medicine Chemokines CXC |
| Zdroj: | Journal of Vascular Surgery. 40(3):536-542 |
| ISSN: | 0741-5214 |
| DOI: | 10.1016/j.jvs.2004.05.023 |
| Popis: | IntroductionDeep venous thrombosis (DVT) resolution involves fibrinolysis, neovascularization, and fibrosis. We hypothesized that promoting neovascularization would accelerate DVT resolution.MethodsA rat model of stasis DVT was produced with proximal ligation of the inferior vena cava (IVC) and all visible tributaries. One μg of interferon inducible protein (IP-10; angiostatic chemokine), basic fibroblast growth factor (bFGF; pro-angiogenic cytokine), epithelial neutrophil activating protein (ENA-78; pro-angiogenic chemokine), or saline solution control was injected into the IVC after ligation, and then via tail vein injection daily until sacrifice at either 4 or 8 days. Peripheral blood counts were measured, and thrombus weight was recorded at sacrifice. Laser Doppler in vivo imaging was used to estimate post-thrombotic IVC blood flow. Immunohistologic assessment of the thrombosed IVC for polymorphonuclear neutrophils (PMNs), monocytes (ED-1), and laminin (neovascular channels) was performed or the thrombus was separated from the IVC and assayed for keratinocyte cytokine (KC), monocyte chemotactic protein-1 (MCP-1), bFGF with enzyme-linked immunosorbent assay (ELISA), and total collagen with a direct colorimetric assay.ResultsPeripheral blood and intrathrombus PMNs and monocytes were not significantly different in the treated or control rats. There were no differences in any measure at 4 days. At 8 days, thrombus neovascularity, but not weight or collagen content, was increased in rats treated with bFGF or ENA-78 compared with control rats (17.6 ± 0.93, 16.2 ± 0.97 vs 13.2 ± 0.79; channels/5 high-power fields (hpf; n = 6-10; P < .05). Post DVT IVC blood flow was significantly increased in bFGF-treated rats but not in rats treated with IP-10 or ENA-78, as compared with control rats. Rats treated with ENA-78 had increased intrathrombus bFGF compared with control rats (85 ± 27 pg/mg protein vs 20 ± 6 pg/mg protein; n = 6; P < .05), but other mediators were not significantly different in treated rats compared with control rats.ConclusionPro-angiogenic compounds increase thrombus neovascularization, but this does not correlate with smaller or less fibrotic DVT. Mechanisms other than neovascularization may be more important to hasten DVT dissolution.AbstractClinical relevanceImproved therapy for deep venous thrombosis (DVT) will ideally increase the rate of thrombus dissolution and eliminate the bleeding risks of anticoagulation. This study evaluated promoting DVT neovascularization with angiogenic chemokines, and, while successful by experimental measures, this did not translate into smaller DVT. Solely promoting thrombus neovascularization will not likely speed resolution. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|